Literature DB >> 18802158

Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.

Julie Lemieux1, Pamela J Goodwin, Kathleen I Pritchard, Karen A Gelmon, Louise J Bordeleau, Thierry Duchesne, Stéphanie Camden, Caroline H Speers.   

Abstract

PURPOSE: It is estimated that only 5% of patients with cancer participate in a clinical trial. Barriers to participation may relate to available protocols, physicians, and patients, but few data exist on barriers related to cancer care environments and protocol characteristics.
METHODS: The primary objective was to identify characteristics of cancer care environments and clinical trial protocols associated with a low recruitment into breast cancer clinical trials. Secondary objectives were to determine yearly recruitment fraction onto clinical trials from 1997 to 2002 in Ontario, Canada, and to compare recruitment fraction among years. Questionnaires were sent to hospitals requesting characteristics of cancer care environments and to cooperative groups/pharmaceutical companies for information on protocols and the number of patients recruited per hospital/year. Poisson regression was used to estimate the recruitment fraction.
RESULTS: Questionnaire completion rate varied between 69% and 100%. Recruitment fraction varied between 5.4% and 8.5% according to year. More than 30% of patients were diagnosed in hospitals with no available trials. In multivariate analysis, the following characteristics were associated with recruitment: use of placebo versus not (relative risk [RR] = 0.80; P = .05), nonmetastatic versus metastatic trial (RR = 2.80; P < .01), and for nonmetastatic trials, protocol allowing an interval of 12 weeks or longer versus less than 12 weeks (from diagnosis, surgery, or end of therapy) before enrollment (RR = 1.36; P < .01).
CONCLUSION: Allowable interval of 12 weeks or longer to randomly assign patients in clinical trials could help recruitment. In our study, absence of an available clinical trial represented the largest barrier to recruitment.

Entities:  

Mesh:

Year:  2008        PMID: 18802158     DOI: 10.1200/JCO.2007.15.3726

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

Review 1.  Reasons for and against participation in studies of medicinal therapies for women with breast cancer: a debate.

Authors:  Gero Luschin; Marion Habersack; Irmina-Anna Gerlich
Journal:  BMC Med Res Methodol       Date:  2012-03-11       Impact factor: 4.615

2.  Should criteria for inclusion in cancer clinical trials be expanded?

Authors:  David E Gerber; Sandi L Pruitt; Ethan A Halm
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

3.  Prevalence of cancer visits by physician specialty, 1997-2006.

Authors:  Benjamin M Craig; Bethany A Bell; Gwendolyn P Quinn; Susan T Vadaparampil
Journal:  J Cancer Educ       Date:  2010-03-25       Impact factor: 2.037

4.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

5.  The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.

Authors:  A Statler; T Radivoyevitch; C Siebenaller; A T Gerds; M Kalaycio; E Kodish; S Mukherjee; C Cheng; M A Sekeres
Journal:  Leukemia       Date:  2016-12-07       Impact factor: 11.528

6.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

7.  Impact of prior cancer on eligibility for lung cancer clinical trials.

Authors:  David E Gerber; Andrew L Laccetti; Lei Xuan; Ethan A Halm; Sandi L Pruitt
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

8.  Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trials.

Authors:  Ricki Carroll; Jules Antigua; Darren Taichman; Harold Palevsky; Paul Forfia; Steven Kawut; Scott D Halpern
Journal:  Clin Trials       Date:  2012-03-02       Impact factor: 2.486

9.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

10.  Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.

Authors:  David E Gerber; Torsten Reimer; Erin L Williams; Mary Gill; Laurin Loudat Priddy; Deidi Bergestuen; Joan H Schiller; Haskell Kirkpatrick; Simon J Craddock Lee
Journal:  J Oncol Pract       Date:  2016-09-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.